NEWS

Recent PRV Article from Harvard Researchers

October 1, 2015

An interesting article that provides the history and examines the success of the Priority Review Voucher program. The author notes that though the value of the voucher has increased from $67.5 million to $350 million, the prospect of payment of this size may be insufficient for large pharmaceutical manufacturers accustomed to substantially higher revenues. Medicines Development however, as a not for profit drug development company dedicated to the development of affordable medicines and vaccines, views this as a significant amount of funding.

Read full article